川芎嗪联合还原型谷胱甘肽治疗酒精性肝病临床分析

Clinical Analysis of Tetramethylpyrazine Combined Glutathione on Alcoholic Liver Disease

目的:探讨川芎嗪联合谷胱甘肽对酒精性肝病的疗效及安全性。方法:选择酒精性肝病病人98例,分成两组,对照组40例,仅采用基础治疗(肌苷、维生素B1、维生素C),治疗组58例,采用基础治疗的同时,给谷胱甘肽1.2g,川芎嗪80mg,二者均静脉滴注,qd×4周,观察患者症状,ALT、AST、GGT、TBIL等项目,判断药物疗效。结果:两组总有效率分别为91.4%和72.5%,均未见不良反应;治疗前后血清生化指标ALT、AST、GGT、TBIL等比较,有显著性差异。结论:川芎嗪联合还原型谷胱甘肽治疗酒精性肝病疗效满意,安全性好。

Objective： To explore the effect and safety of tetramethylpyrazine combined glutathione on alcoholic liver disease. Method： 98 cases alcoholic liver disease were divided into treatment group （58 cases） and control group （40 cases） , 1.2g glutathione and 80mg tetramethy lpyrazine were intravenoused once a day on the basic treatment such as adinosine,VitB1 and VitC for patient in control group. While the patients were given tetramethylpyrazine in treatment group. Then evaluated the effect according to the value of ALT, AST, GGT and TBIL. Result： There＇s no side effect in both group and the total effective rate was 91. 4% and 72.5% in treatment group and control group respectively. There＇s significant difference in serume level of ALT, ASF, GGT and TBIL. Conclusion： It＇s safe and satisfied to treat alcoholic liver disease with tetramethylpyrazine combined with glutathione.